Marker Therapeutics
MRKR
47 hedge funds and large institutions have $5.24M invested in Marker Therapeutics in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 4 closing their positions.
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
4% more funds holding
Funds holding: 45 → 47 (+2)
0.11% less ownership
Funds ownership: 2.45% → 2.34% (-0.11%)
31% less capital invested
Capital invested by funds: $7.56M → $5.24M (-$2.32M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$58.4K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$9.58K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$6.46K |
| 4 |
Jane Street
New York
|
+$4.27K |
| 5 |
Renaissance Technologies
New York
|
+$4.04K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAM
AR Asset Management
West Hollywood,
California
|
-$103K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$92K |
| 3 |
MAA
Matrix Asset Advisors
White Plains,
New York
|
-$51.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$14.8K |
| 5 |
Two Sigma Investments
New York
|
-$13.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$69 | +20 | +2,000% |
|
MRKR Hedge Fund Activity: Q4 2022 in Review
47 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q4 2022, worth a combined $5.24M — down 31% from $7.56M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new MRKR positions and 4 closed out — a net gain of 4 holders — while 10 added to existing stakes and 9 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $58.4K. The largest seller was AR Asset Management, exiting entirely with an estimated $103K sold.
- 47 institutional investors held Marker Therapeutics (MRKR) as of Q4 2022, up from 45 in Q3 2022.
- Funds reported $5.24M of Marker Therapeutics stock for Q4 2022, down 31% quarter-over-quarter.
- 8 funds opened new Marker Therapeutics positions in Q4 2022 and 4 closed out, a net change of +4 holders.
- The largest Marker Therapeutics buyer in Q4 2022 was Millennium Management, an estimated $58.4K added.
- The largest Marker Therapeutics seller in Q4 2022 was AR Asset Management, an estimated $103K sold.
Based on aggregated 13F filings for Q4 2022.